United Therapeutics
UTHR
373 hedge funds and large institutions have $6.01B invested in United Therapeutics in 2017 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 155 increasing their positions, 130 reducing their positions, and 63 closing their positions.
19% more repeat investments, than reductions
Existing positions increased: 155 | Existing positions reduced: 130
3.47% less ownership
Funds ownership: 106.25% → 102.79% (-3.5%)
7% less capital invested
Capital invested by funds: $6.46B → $6.01B (-$451M)
9% less funds holding
Funds holding: 411 → 373 (-38)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
51% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 63
74% less call options, than puts
Call options by funds: $29.9M | Put options by funds: $114M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$56.5M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$53.8M |
| 3 |
Goldman Sachs
New York
|
+$52.5M |
| 4 |
JP Morgan Chase
New York
|
+$47.2M |
| 5 |
Renaissance Technologies
New York
|
+$41.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
-$208M |
| 2 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
-$107M |
| 3 |
LSV Asset Management
Chicago,
Illinois
|
-$98.8M |
| 4 |
CCM
Consonance Capital Management
New York
|
-$86.9M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$41.5M |
UTHR Hedge Fund Activity: Q2 2017 in Review
373 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q2 2017, worth a combined $6.01B — down 7% from $6.46B a quarter earlier.
Sellers outnumbered buyers: 63 funds closed out of UTHR and 31 opened new positions — a net loss of 32 holders — while 130 trimmed existing stakes and 155 added.
The largest buyer was AQR Capital Management, adding an estimated $56.5M. The largest seller was Scopia Capital Management, cutting an estimated $208M.
- 373 institutional investors held United Therapeutics (UTHR) as of Q2 2017, down from 411 in Q1 2017.
- Funds reported $6.01B of United Therapeutics stock for Q2 2017, down 7% quarter-over-quarter.
- 31 funds opened new United Therapeutics positions in Q2 2017 and 63 closed out, a net change of -32 holders.
- The largest United Therapeutics buyer in Q2 2017 was AQR Capital Management, an estimated $56.5M added.
- The largest United Therapeutics seller in Q2 2017 was Scopia Capital Management, an estimated $208M sold.
Based on aggregated 13F filings for Q2 2017.